Oral cyclosporine A - the current picture of its liposomal and other delivery systems

[1] O’Neal, M.J., Heckelman, P.E., Koch, C.B., Roman, K.J., Kenny, C.M. and D’Arecca, M.R. (Eds) The Merck Index - an encyclopedia of chemicals, drugs, and biologicals, 14th edition, Merck & Co., Inc., Whitehouse Station, NJ, USA, 2006, 2753. Search in Google Scholar

[2] Laven, A. Biosynthesis and mechanism of action of cyclosporins. Prog. Med. Chem. 33 (1996) 53–97. http://dx.doi.org/10.1016/S0079-6468(08)70303-510.1016/S0079-6468(08)70303-5Search in Google Scholar

[3] Wenger, R.M. Total synthesis of “cyclosporin A” and “cyclosporin H”, two fungal metabolites isolated from species Tolypocladium inflatum Gams. Helv. Chim. Acta 67 (1984) 503–515. http://dx.doi.org/10.1002/hlca.1984067022010.1002/hlca.19840670220Search in Google Scholar

[4] Italia, J.L., Bhardwaj, V. and Kumar, M.N.V.R. Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. Drug Discov. Today 11 (2006) 846–854. http://dx.doi.org/10.1016/j.drudis.2006.07.01510.1016/j.drudis.2006.07.015Search in Google Scholar PubMed

[5] Kallen, J., Mikol, V., Quesniaux, V.F.J., Walkinshaw, M.D., Schneider-Scherzer, E.S., Schorgendorfer, K., Weber, G. and Fliri, H.G. Cyclosporins: recent developments in biosynthesis, pharmacology and biology, and clinical applications. in: Biotechnology, a Multivolume Comprehensive Treatise (Rehm, H.J., Reed, G., Puhler, A. and vonDohren, H., Eds), Vol.7, VCH Verlagsgesellschaft, Weinheim, 1997, 535–591. Search in Google Scholar

[6] Borel, J.F. Pharmacology and Pharmacokinetics of cyclosporin A. Transpl. Clin. Immunol. 13 (1981) 3–6. Search in Google Scholar

[7] Schumacher, A. and Nordheim, A. Progress towards a molecular understanding of cyclosporine A-mediated immunosupression. Clin. Investig. 70 (1992) 773–779. http://dx.doi.org/10.1007/BF0018074710.1007/BF00180747Search in Google Scholar PubMed

[8] Ready, A. Experience with cyclosporine. Transplant. Proc. 36 (2004) 135S–138S. http://dx.doi.org/10.1016/j.transproceed.2003.12.04910.1016/j.transproceed.2003.12.049Search in Google Scholar PubMed

[9] Busauschina, A. Cyclosporine nephrotoxicity. Transplant. Proc. 36 (2004) 2295–2335. http://dx.doi.org/10.1016/j.transproceed.2004.01.02110.1016/j.transproceed.2004.01.021Search in Google Scholar PubMed

[10] Durak, I., Karabacak, H.I., Buyukkocak, S., Cimen, M.Y., Kacmaz, M., Omeroglu, E. and Ozturk, H.S. Impaired antioxidant defense system in the kidney tissues from rabbits treated with cyclosporine. Protective effects of vitamins E and C. Nephron 78 (1998) 207–211. http://dx.doi.org/10.1159/00004491210.1159/000044912Search in Google Scholar PubMed

[11] Rezzani, R., Buffoli, B., Rodella, L., Stacchioti, A. and Bianchi, R. Protective role of melatonin in cyclosporine A-induced oxidative stress in rat liver. Int. Immunopharmacol. 5 (2005) 1397–1405. http://dx.doi.org/10.1016/j.intimp.2005.03.02110.1016/j.intimp.2005.03.021Search in Google Scholar PubMed

[12] Kahan, B.D. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant. Proc. 36 (2004) 378s–391s. http://dx.doi.org/10.1016/j.transproceed.2004.01.09110.1016/j.transproceed.2004.01.091Search in Google Scholar PubMed

[13] Petcher, T.J., Weber, H. and Ruegger, A. Crystal and molecular structure of an iodo-derivative of the cyclic undecapeptide cyclosporin A. Helv. Chim. Acta 59 (1976) p. 10.1002/hlca.19760590509Search in Google Scholar PubMed

[14] El Tayar, N., Mark, A.E., Vallat, P., Brunne, R.M., Testa, B. and van Gunsteren, W.F. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J. Med. Chem. 36 (1993) 3757–3764. http://dx.doi.org/10.1021/jm00076a00210.1021/jm00076a002Search in Google Scholar PubMed

[15] Sigma. Product Information. Cyclosporin A. 1996 Sigma Chemical Co. Search in Google Scholar

[16] Lechuga-Ballesteros, D., Abdul-Fattach, A., Stevenson, C.L. and Bennett, D.B. Properties and stability of a liquid crystal form of cyclosporine — the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. J. Pharm. Sci. 92 (2003) 1821–1831. http://dx.doi.org/10.1002/jps.1044410.1002/jps.10444Search in Google Scholar PubMed

[17] Ismailos, G., Peppas, C., Dressman, J. and Macheras, P. Unusual solubility behavior of cyclosporin A in aqueous media. J. Pharm. Pharmacol. 43 (1991) 287–289. Search in Google Scholar

[18] Schote, U., Ganz, P., Fahr, A. and Seelig, J. Interactions of cyclosporines with lipid membranes as studied by solid-state nuclear magnetic resonance spectroscopy and high-sensitivity titration calorimetry. J. Pharm. Sci. 91 (2002) 856–867. http://dx.doi.org/10.1002/jps.1007110.1002/jps.10071Search in Google Scholar PubMed

[19] Hasumi, H., Nishikawa, T. and Ohtani, H. Effect of temperature on molecular structure of cyclosporin A. Biochem. Mol. Biol. Int. 34 (1994) 505–511. Search in Google Scholar

[20] Mueller, R.H., Runge, S., Ravelli, V., Mehnert, W., Thunemann, A.F. and Souto, E.B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int. J. Pharm. 317 (2006) 82–89. http://dx.doi.org/10.1016/j.ijpharm.2006.02.04510.1016/j.ijpharm.2006.02.045Search in Google Scholar PubMed

[21] Hamel, A.R., Hubler, F., Carrupt, A., Wenger, R.M. and Mutter, M. Cyclosporin A prodrugs: design, synthesis and biophysical properties. J. Peptide Res. 63 (2004) 147–154. http://dx.doi.org/10.1111/j.1399-3011.2003.00111.x10.1111/j.1399-3011.2003.00111.xSearch in Google Scholar PubMed

[22] Lallemand, F., Perottet, P., Felt-Baeyens, O., Kloeti, W., Philippoz, F., Marfurt, J., Besseghir, K. and Gurny, R. A water-soluble prodrug of cyclosporine A for ocular application: a stability study. Eur. J. Pharm. Sci. 26 (2005) 124–129. http://dx.doi.org/10.1016/j.ejps.2005.05.00310.1016/j.ejps.2005.05.003Search in Google Scholar PubMed

[23] Ran, Y., Zhao, L., Xu, Q. and Yalkowsky, S.H. Solubilization of Cyclosporin A. AAPS Pharm. Sci. Tech. 2 (2001) 2. http://dx.doi.org/10.1208/pt02010210.1208/pt020102Search in Google Scholar PubMed PubMed Central

[24] Weber, C., Wider, G., von Freyberg, B., Traber, R., Braun, W., Widmer, H. and Wuthrich, K. The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution. Biochemistry 30 (1991) 6563–6574. http://dx.doi.org/10.1021/bi00240a02910.1021/bi00240a029Search in Google Scholar PubMed

[25] Altschuh, D., Vix, O., Rees, B. and Thierry, J.C. A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex. Science 256 (1992) 92–94. http://dx.doi.org/10.1126/science.156606210.1126/science.1566062Search in Google Scholar PubMed

[26] Klages, J., Neubauer, C., Coles, M., Kessler, H. and Luy, B. Structure refinement of cyclosporin A in chloroform by using RDCs measured in a stretched PDMS-gel. Chembiochem 6 (2005) 1672–1678. http://dx.doi.org/10.1002/cbic.20050014610.1002/cbic.200500146Search in Google Scholar PubMed

[27] Kajitani, K., Fujihashi, M., Kobayashi, Y., Shimizu, S., Tsujimoto, Y. and Miki, K. Crystal structure of human cyclophilin D in complex with its inhibitor, cyclosporine A at 0.96-Å resolution. Proteins 70 (2008) 1635–1639. http://dx.doi.org/10.1002/prot.2185510.1002/prot.21855Search in Google Scholar

[28] Ouyang, C., Choice, E., Holland, J., Meloche, M. and Madden, T.D. Liposomal cyclosporine. Characterization of drug incorporation and interbilayer exchange. Transplantation 60 (1995) 999–1006. http://dx.doi.org/10.1097/00007890-199511150-0002110.1097/00007890-199511150-00021Search in Google Scholar

[29] Fahr, A. and Reiter, G. Biophysical characterisation of liposomal delivery systems for lipophilic drugs: Cyclosporin A as an example. Cell. Mol. Biol. Lett. 4 (1999) 611–623. Search in Google Scholar

[30] Fahr, A., Holz, M. and Fricker, G. Liposomal formulations of Cyclosporin A: influence of lipid type and dose on pharmacokinetics. Pharm. Res. 12 (1995) 1189–1197. http://dx.doi.org/10.1023/A:101622021192510.1023/A:1016220211925Search in Google Scholar

[31] Fahr, A., Nimmerfall, F. and Wenger, R. Interactions of Cyclosporin A and some derivatives with model membranes: Binding and ion permeability changes. Transplant. Proc. 26 (1994) 2837–2841. Search in Google Scholar

[32] Fahr, A., van Hoogevest, P., May, S., Bergstrand, N. and Leigh, M.L.S. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur. J. Pharm. Sci. 26 (2005) 251–265. http://dx.doi.org/10.1016/j.ejps.2005.05.01210.1016/j.ejps.2005.05.012Search in Google Scholar

[33] Lambros, M.P. and Rahman, Y.E. Effects of cyclosporin A on model lipid membranes. Chem. Phys. Lipids 131 (2004) 63–69. http://dx.doi.org/10.1016/j.chemphyslip.2004.04.00210.1016/j.chemphyslip.2004.04.002Search in Google Scholar

[34] Soderlund, T., Lehtonen, J.Y.A. and Kinnunen, P.K.J. Interactions of cyclosporin A with phospholipid membranes: effect of cholesterol. Mol. Pharmacol. 55 (1999) 32–38. Search in Google Scholar

[35] Wiedmann, T.S., Trouard, T., Shekar, S.C., Polikandritou, M. and Rahman, Y.E. Interaction of cyclosporin A with dipalmitoylphosphatidylcholine. Biochim. Biophys. Acta 1023 (1990) 12–18. http://dx.doi.org/10.1016/0005-2736(90)90003-710.1016/0005-2736(90)90003-7Search in Google Scholar

[36] Stuhne-Sekalec, L. and Stanacev, N.Z. Liposomes as cyclosporin A carriers: the influence of ordering of hydrocarbon chains of phosphatidylglycerol liposomes on the association with and topography of cyclosporin A. J. Microencapsul. 8 (1991) 283–294. http://dx.doi.org/10.3109/0265204910906955410.3109/02652049109069554Search in Google Scholar

[37] Freise, C.E., Liu, T., Hong, K.L., Osorio, R.W., Papahadjopoulos, D., Ferrell, L., Ascher, N.L. and Roberts, J.P. The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome. Transplantation 57 (1994) 928–932. http://dx.doi.org/10.1097/00007890-199403270-0002710.1097/00007890-199403270-00027Search in Google Scholar

[38] Thiel, G., Hermle, M. and Brunner, F.P. Acutely impaired renal function during intravenous administration of cyclosporine A: a cremophor side-effect. Clin. Nephrol. 25 (1986) S40–S42. Search in Google Scholar

[39] Alangary, A.A., Bayomi, M.A., Khidr, S.N., Almeshal, M.A. and Aldardiri, M. Characterization, stability and in vivo targeting of liposomal formulations containing cyclosporine. Int. J. Pharm. 114 (1995) 221–225. http://dx.doi.org/10.1016/0378-5173(94)00243-X10.1016/0378-5173(94)00243-XSearch in Google Scholar

[40] Amidon, G.L., Lennernas, H., Shah, V.P. and Crison, J.R. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413–420. http://dx.doi.org/10.1023/A:101621280428810.1023/A:1016212804288Search in Google Scholar

[41] Mithani, S.D., Bakatselou, V., TenHoor, C.N. and Dressman, J.B. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm. Res. 13 (1996) 163–167. http://dx.doi.org/10.1023/A:101606222456810.1023/A:1016062224568Search in Google Scholar

[42] Wu, C.Y., Benet, L.Z., Hebert, M.F., Gupta, S.K., Rowland, M., Gomez, D.Y. and Wacher, V.J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58 (1995) 492–497. http://dx.doi.org/10.1016/0009-9236(95)90168-X10.1016/0009-9236(95)90168-XSearch in Google Scholar

[43] Kelly, P.A., Wang, H., Napoli, K.L., Kahan, B.D. and Strobel, H.W. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug Metab. Pharmacokinet. 24 (1999) 321–328. 10.1007/BF03190040Search in Google Scholar

[44] Hebert, M.F. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug. Deliv. Rev. 27 (1997) 201–214. http://dx.doi.org/10.1016/S0169-409X(97)00043-410.1016/S0169-409X(97)00043-4Search in Google Scholar

[45] Fricker, G., Drewe, J., Huwyler, J., Gutmann, H. and Beglinger, C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro in vivo correlation. Br. J. Pharmacol. 118 (1996) 1841–1847. Search in Google Scholar

[46] Lown, K.S., Mayo, R.R., Leichtman, A.B., Hsiao, H.L., Turgeon, D.K., Schmiedlin-Ren, P., Brown, M.B., Guo, W., Rossi, S.J., Benet, L.Z. and Watkins, P.B. Role of intestinal P- glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62 (1997) 248–260. http://dx.doi.org/10.1016/S0009-9236(97)90027-810.1016/S0009-9236(97)90027-8Search in Google Scholar

[47] Johnston, A., Marsden, J.T., Hla, K.K., Henry, J.A. and Holt, D.W. The effect of vehicle on oral absorption of cyclosporin. Br. J. Clin. Pharmacol. 21 (1986) 331–333. Search in Google Scholar

[48] Kovarik, J.M., Mueller, E.A., van Bree, J.B., Tetzloff, W. and Kutz, K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83 (1994) 444–446. http://dx.doi.org/10.1002/jps.260083033610.1002/jps.2600830336Search in Google Scholar

[49] Dunn, C.J., Wagstaff, A.J., Perry, C.M., Plosker, G.L. and Goa, K.L. Cyclosporin. An updated review of the pharmacokinetic properties, clinical efficiacy and tolerability of a microemulsion-based formulation (Neoral®) in organ transplantation. Drugs 61 (2001) 1957–2016. http://dx.doi.org/10.2165/00003495-200161130-0000610.2165/00003495-200161130-00006Search in Google Scholar

[50] Cattaneo, D., Perico, N. and Remuzzi, G. Generic cyclosporine formulations: more open questions than answers. Transpl. Int. 18 (2005) 371–378. http://dx.doi.org/10.1111/j.1432-2277.2005.00078.x10.1111/j.1432-2277.2005.00078.xSearch in Google Scholar

[51] Pollard, S., Nashan, B., Johnston, A., Hoyer, P., Belitsky, P., Keown, P. and Helderman, H. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin. Ther. 25 (2003) 1654–1669. http://dx.doi.org/10.1016/S0149-2918(03)80161-310.1016/S0149-2918(03)80161-3Search in Google Scholar

[52] Venkataram, S., Awni, W.M., Jordan, K. and Rahman, Y.E. Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. J. Pharm. Sci. 79 (1990) 216–219. http://dx.doi.org/10.1002/jps.260079030710.1002/jps.2600790307Search in Google Scholar PubMed

[53] Aramaki, Y., Tomizawa, H., Hara, T., Yachi, K., Kikuchi, H. and Tsuchiya, S. Stability of liposomes in vitro and their uptake by rat Peyer’s patches following oral administration. Pharm. Res. 10 (1993) 1228–1231. http://dx.doi.org/10.1023/A:101893680627810.1023/A:1018936806278Search in Google Scholar

[54] Guo, J., Ping, Q. and Chen, Y. Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and sandimmun neoral. Int. J. Pharm. 216 (2001) 17–21. http://dx.doi.org/10.1016/S0378-5173(00)00680-310.1016/S0378-5173(00)00680-3Search in Google Scholar

[55] Shah, N.M., Parikh, J., Namdeo, A., Subramanian, N. and Bhowmick, S. Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. J. Nanosci. Nanotechnol. 6 (2006) 2967–2973. http://dx.doi.org/10.1166/jnn.2006.40310.1166/jnn.2006.403Search in Google Scholar

[56] Al-Meshal, M.A., Khidr, S.H., Bayomi, M.A. and Al-Angary, A.A. Oral administration of liposomes containing cyclosporine: a pharmacokinetic study. Int. J. Pharm. 168 (1998) 163–168. http://dx.doi.org/10.1016/S0378-5173(98)00066-010.1016/S0378-5173(98)00066-0Search in Google Scholar

[57] Bravo Gonzalez, R.C., Huwyler, J., Walter, I., Mountfield, R. and Bittner, B. Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. Int. J. Pharm. 245 (2002) 143–151. http://dx.doi.org/10.1016/S0378-5173(02)00339-310.1016/S0378-5173(02)00339-3Search in Google Scholar

[58] Murdan, S., Andrysek, T. and Son, D. Novel gels and their dispersions — oral drug delivery systems for ciclosporin. Int. J. Pharm. 300 (2005) 113–124. Search in Google Scholar

[59] Kim, S.J., Choi, H.K. and Lee, Y.B. Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion in rats. Int. J. Pharm. 249 (2002) 149–156. http://dx.doi.org/10.1016/S0378-5173(02)00490-810.1016/S0378-5173(02)00490-8Search in Google Scholar

[60] Kim, S.J., Choi, H.K., Suh, S.P. and Lee, Y.B. Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion and microsphere formulations in rabbits. Eur. J. Pharm. Sci. 15 (2002) 497–502. http://dx.doi.org/10.1016/S0928-0987(02)00048-910.1016/S0928-0987(02)00048-9Search in Google Scholar

[61] Woo, J.S., Piao, M.G., Li, D.X., Ryu, D.S., Choi, J.Y., Kim, J.A., Kim, J.H., Jin, S.G., Kim, D.D., Lyoo, W.S., Yong, C.S. and Choi, H.G. Development of cyclosporin A-loaded hyaluronic microsphere with enhanced oral bioavailability. Int. J. Pharm. 345 (2007) 134–141. http://dx.doi.org/10.1016/j.ijpharm.2007.08.05010.1016/j.ijpharm.2007.08.050Search in Google Scholar

[62] Lee, E.J., Lee, S.W., Choi, H.G. and Kim, C.K. Bioavailibility of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. Int. J. Pharm. 218 (2001) 125–131. http://dx.doi.org/10.1016/S0378-5173(01)00621-410.1016/S0378-5173(01)00621-4Search in Google Scholar

[63] Zhang, Q., Yie, G., Li, Y., Yang, Q. and Nagai, T. Studies on the cyclosporin A loaded stearic acid nanoparticles. Int. J. Pharm. 200 (2000) 153–159. http://dx.doi.org/10.1016/S0378-5173(00)00361-610.1016/S0378-5173(00)00361-6Search in Google Scholar

[64] Francis, M.F., Cristea, M., Yang, Y. and Winnik, F.M. Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across Caco-2 cells. Pharm. Res. 22 (2005) 209–219. http://dx.doi.org/10.1007/s11095-004-1188-010.1007/s11095-004-1188-0Search in Google Scholar

[65] Lee, W.K., Park, J.Y., Yang, E.H., Suh, H., Kim, S.H., Chung, D.S., Choi, K., Yang, C.W. and Park, J.S. Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. J. Control. Release 84 (2002) 115–123. http://dx.doi.org/10.1016/S0168-3659(02)00239-010.1016/S0168-3659(02)00239-0Search in Google Scholar

[66] Italia, J.L., Bhatt, D.K., Bhardwaj, V., Tikoo, K. and Kumar, M.N. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J. Control. Release 119 (2007) 197–206. http://dx.doi.org/10.1016/j.jconrel.2007.02.00410.1016/j.jconrel.2007.02.004Search in Google Scholar

[67] Gref, R., Quellec, P., Sanchez, A., Calvo, P., Dellacherie, E. and Alonso, M.J. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm. 51 (2001) 111–118. http://dx.doi.org/10.1016/S0939-6411(00)00143-010.1016/S0939-6411(00)00143-0Search in Google Scholar

[68] Molpeceres, J., Chacón, M., Guzmán, M., Berges, L. and del Rosario Aberturas, M. A polycaprolactone nanoparticle formulation of cyclosporine improves the prediction of area under the curve using a limited sampling strategy. Int. J. Pharm. 187 (1999) 101–113. http://dx.doi.org/10.1016/S0378-5173(99)00177-510.1016/S0378-5173(99)00177-5Search in Google Scholar

[69] Varela, M.C., Guzman, M., Molpeceres, J., del Rosario Aberturas, M., Rodriguez-Puyol, D. and Rodriguez-Puyol, M. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur. J. Pharm. Sci. 12 (2001) 471–478. http://dx.doi.org/10.1016/S0928-0987(00)00198-610.1016/S0928-0987(00)00198-6Search in Google Scholar

[70] Dai, J., Nagai, T., Wang, X., Zhang, T., Meng, M. and Zhang, Q. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm. 280 (2004) 229–240. http://dx.doi.org/10.1016/j.ijpharm.2004.05.00610.1016/j.ijpharm.2004.05.006Search in Google Scholar

[71] Wang, X.Q., Huang, J., Dai, J.D., Zhang, T., Lu, W.L., Zhang, H., Zhang, X., Wang, J.C. and Zhang, Q. Long-term studies on the stability and oral bioavailibility of cyclosporine A nanoparticle colloid. Int. J. Pharm. 322 (2006) 146–153. http://dx.doi.org/10.1016/j.ijpharm.2006.05.02110.1016/j.ijpharm.2006.05.021Search in Google Scholar

[72] Wang, X.Q.W., Dai, J.D., Chen, Z., Zhang, T., Xia, G.M., Nagai, T. and Zhang, Q. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J. Control Release 97 (2004) 421–429. Search in Google Scholar

[73] El-Shabouri, M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm. 249 (2002) 101–108. http://dx.doi.org/10.1016/S0378-5173(02)00461-110.1016/S0378-5173(02)00461-1Search in Google Scholar

[74] Cheng, W.P., Gray, A.I., Tetley, L., Hang Tle, B., Schätzlein, A.G. and Uchegbu, I.F. Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds. Biomacromolecules 7 (2006) 1509–1520. http://dx.doi.org/10.1021/bm060130l10.1021/bm060130lSearch in Google Scholar PubMed

[75] Liu, C., Zhu, S.J., Zhou, Y., Wei, Y.P. and Pei, Y.Y. Enhancement of dissolution of cyclosporine A using solid dispersions with polyoxyethylene (40) stearate. Pharmazie 61 (2006) 681–684. Search in Google Scholar

[76] Liu, C., Wu, J., Shi, B., Zhang, Y., Gao, T. and Pei, Y. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev. Ind. Pharm. 32 (2006) 115–123. http://dx.doi.org/10.1080/0363904050038857310.1080/03639040500388573Search in Google Scholar PubMed

[77] Mueller, R.H., Runge, S.A., Ravelli, V., Thunemann, A.F., Mehnert, W. and Souto, E.B. Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 68 (2008) 535–544. http://dx.doi.org/10.1016/j.ejpb.2007.07.00610.1016/j.ejpb.2007.07.006Search in Google Scholar PubMed

[78] Bekerman, T., Golenser, J. and Domb, A. Cyclosporin nanoparticulate lipospheres for oral administration. J. Pharm. Sci. 93 (2004) 1264–1270. http://dx.doi.org/10.1002/jps.2005710.1002/jps.20057Search in Google Scholar PubMed

[79] Van Drooge, D.J., Hinrichs, W.L. and Frijlink, H.W. Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvent. J. Pharm. Sci. 93 (2004) 713–725. http://dx.doi.org/10.1002/jps.1059010.1002/jps.10590Search in Google Scholar PubMed

[80] Miyake, K., Arima, H., Irie, T., Hirayama, F. and Uekama, K. Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats. Biol. Pharm. Bull. 22 (1999) 66–72. Search in Google Scholar

[81] Sharma, P., Varma, M.V.S., Chwala, H.P.S. and Panchagnula, R. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Il Farmaco 60 (2005) 884–893. http://dx.doi.org/10.1016/j.farmac.2005.08.00810.1016/j.farmac.2005.08.008Search in Google Scholar PubMed